Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG

With modern chemotherapy, approximately 90% of patients with pediatric acute lymphoblastic leukemia are now cured. However, subsets of patients can be identified who remain at very high risk of relapse with expected 4-year disease-free survival rates <80%; such patients are appropriate candidates...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, Michael J., Salzer, Wanda L., Devidas, Meenakshi, Dai, Yunfeng, Gore, Lia, Hilden, Joanne M., Larsen, Eric, Rabin, Karen R., Zweidler-McKay, Patrick A., Borowitz, Michael J., Wood, Brent, Heerema, Nyla A., Carroll, Andrew J., Winick, Naomi, Carroll, William L., Raetz, Elizabeth A., Loh, Mignon L., Hunger, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518909/
https://www.ncbi.nlm.nih.gov/pubmed/30545921
http://dx.doi.org/10.3324/haematol.2018.204545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518909/
https://www.ncbi.nlm.nih.gov/pubmed/30545921
http://dx.doi.org/10.3324/haematol.2018.204545

Ejemplares similares